Dasatinib Is Preferentially Active in the Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Marissa L. Cann, Laura E. Herring, Lauren L. Haar, Thomas S.K. Gilbert, Dennis Goldfarb, Kristy L. Richards, Lee M. Graves, David S. Lawrence

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, and at least one-third of its patients relapse after treatment with the current chemotherapy regimen, R-CHOP. By gene-expression profiling, patients with DLBCL can be categorized into two clinically relevant subtypes: activated B-cell (ABC) and germinal center B-cell (GCB) DLBCL. Patients with the ABC subtype have a worse prognosis than those with GCB, and the subtype is defined by chronic, over-active signaling through the B-cell receptor and NF-κB pathways. We examined the effects of the Src family kinase (SFK) inhibitor dasatinib in a panel of ABC and GCB DLBCL cell lines and found that the former are much more sensitive to dasatinib than the latter. However, using multiplexed inhibitor bead coupled to mass spectrometry (MIB/MS) kinome profiling and Western blot analysis, we found that both subtypes display inhibition of the SFKs in response to dasatinib after both short- and long-term treatment. The MIB/MS analyses revealed that several cell-cycle kinases, including CDK4, CDK6, and the Aurora kinases, are down-regulated by dasatinib treatment in the ABC, but not in the GCB, subtype. The present findings have potential implications for the clinical use of dasatinib for the treatment of ABC DLBCL, either alone or in combination with other agents.

Original languageEnglish
Pages (from-to)522-534
Number of pages13
JournalJournal of Proteome Research
Volume18
Issue number1
DOIs
StatePublished - Jan 4 2019

Keywords

  • Src family kinases
  • cell-cycle kinases
  • dasatinib
  • kinase
  • lymphoma
  • proteomics

Fingerprint

Dive into the research topics of 'Dasatinib Is Preferentially Active in the Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma'. Together they form a unique fingerprint.

Cite this